Sotera Health Company (NASDAQ:SHC) Q3 2023 Earnings Call Transcript

Michael Petras: Yes. Casey, this is Michael. Yes, bioprocessing has an impact on the guide. And then I would also tell you, it’s a really mixed bag on the medical device side. We have some categories doing really well and others not, and some of it’s really tied to our customers and some of the inventory challenges and supply chain challenges.

Casey Woodring: Got it. Thank you very much.

Operator: This concludes our question-and-answer session. I would like to turn the conference back over to Michael Petras for any closing remarks.

Michael Petras: Thank you. I want to emphasize what a great business this is. We produced 6% top-line growth and 7% bottom-line growth in the quarter, and we also generated strong operating cash flow. We remain focused on living our mission of Safeguarding Global Health, and we like to thank our customers and investors for their continued support throughout the year. So thank you, and have a good day. Bye-bye.

Operator: The conference has now concluded. Thank you for attending today’s presentation. You may now disconnect.